Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer
10.3760/cma.j.issn.0253-3766.2019.09.007
- VernacularTitle: 乳腺癌原发灶和转移灶中雌激素受体孕激素受体人表皮生长因子受体2和Ki-67的表达变化
- Author:
Yuan YUAN
1
;
Sainan HU
1
;
Jin GAO
1
;
Qiao YU
2
;
Yiqin HU
2
;
Xinyu XU
3
;
Zhigang GAO
4
;
Jin ZHANG
5
;
Zhe ZHANG
3
;
Yue TENG
1
;
Lili ZHANG
1
Author Information
1. Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China
2. Department of Breast Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China
3. Department of Pathology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China
4. Department of Ultrasonics, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China
5. Department of CT, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China
- Publication Type:Clinical Trail
- Keywords:
Breast neoplasms;
Primary;
Metastasis;
Hormone receptor;
HER-2;
Prognosis
- From:
Chinese Journal of Oncology
2019;41(9):681-685
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression discordances of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor2 (HER-2) and Ki-67 in primary and metastatic breast cancer specimens and explore the clinical significances.
Methods:Biopsies of metastatic lesions were performed in 203 patients with breast cancer recurrence and metastasis indicated by physical examination and/or imaging examination. We confirmed pathological properties and assessed the expressions of ER, PR, HER-2 and Ki-67 in primary and metastatic lesions, their relationships with prognosis were also analyzed.
Results:Biopsy failed in 3 patients, the pathology and immunohistochemitry results of metastatic lesions were not obtained. One person was diagnosed as tuberculosis and another was primary lung cancer. Among the 198 cases of primary and metastatic lesions, the discordance rates of ER, PR, HER-2 and Ki-67 were 27.3%, 34.3%, 11.8% and 15.1%, respectively.The expressions of ER, HER-2 and Ki-67 were not significantly different between the primary and metastatic lesions, however, the expressions of PR were more likely to turn negative in the metastases (P<0.001). The disease-free survival (DFS) of patients with ER, PR positive, HER-2 negative and low expression of Ki-67 in metastatic lesion was much longer (P<0.05).
Conclusions:The expressions of ER, PR, HER-2 and Ki-67 in metastatic lesions are associated with the prognosis of breast cancer patients.Their expression discordances between primary and metastatic lesions can guide the treatment and evaluate the risks of recurrence and prognosis.
